Associations of VO2peak to significant predictors.

Slides:

Advertisements

Similar presentations

Lacto-ovo vegetarian group

Advertisements

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

Multivariable model of abatacept retention in biologic-naïve patients.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Frequency of patients in flare at each time point over 3 months

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.

Univariate predictors of (A) ASDAS ID (<1

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Factors influencing the relationship between disease activity (as measured with the ASDAS) and radiographic progression (as measured with the 2-year mSASSS.

The volume per centre plotted against clinical outcomes which included Hospital Anxiety and Depression Scale (HADS) score, exercise 150 min, smoking, body.

Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

Independent baseline predictors of non-remission at 24 months of follow-up in the SWEFOT trial population. Independent baseline predictors of non-remission.

Changes in clinical outcome measures over 24 months on a continuous scale in the whole SWEFOT trial population with available baseline BMI categories.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Associations between type of MI and incident HF

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Results from the second Delphi step showing the percentage of rated domains that the experts agreed on as domains for the annual systemic assessment of.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Distribution of swelling and tenderness in joints with or without x-ray progression. Distribution of swelling and tenderness in joints with or without.

Employment of patients with AS compared with controls, by BASDAI

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Determinants of moderate Cardiovascular Health Index Score (CHIS) (achieving three or more risk factor targets). Determinants of moderate Cardiovascular.

Multivariable analysis of Clinical Disease Activity Index (CDAI) over time modelled with a cubic effect of time and adjusted for age, gender, disease duration,

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Subject disposition through week 156 of treatment

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Satisfaction with control of RA

Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.

Summary multiple regression charts for (A) PROFAD physical fatigue and (B) PROFAD mental fatigue scores. Summary multiple regression charts for (A) PROFAD.

Classification tree with the selected characteristics.

Risk of cardiovascular disease mortality by cardiorespiratory fitness and body mass index categories, 2316 men with type 2 diabetes at baseline, 179 deaths.

Network graph illustrating the relation between the assessed structural abnormalities on different locations within the knee joint in the total NEO study.

The combined effects of low sodium and the DASH diet according to baseline blood pressure. The combined effects of low sodium and the DASH diet according.

Multivariable model of adjusted

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.

WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.

Multivariate Cox proportional hazards model of time to first serious infectious events. Multivariate Cox proportional hazards model of time to first serious.

NRDC and TNF-α increase in synovial fluid from patients with RA

HR for mortality in ischemic heart disease.

HR for myocardial infarction.

The distribution of systolic blood pressure (SBP) in male (blue) and female (red) athletes with mean values (SD) presented for each sex (panel A). The.

Relationship between 6-month all-cause mortality and the three types of heart failure adjusted for age ≥75 years, peripheral edema at admission, systolic.

Forest plot showing survival c-statistics for selected models, applied to the testing cohort. Forest plot showing survival c-statistics for selected models,

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

A – Demographic, Anthropometric and Clinical correlates of plasma NT-proBNP levels stratified by race: Multivariable Regression Results (Multivariable.

Receiver operating characteristic curve showing results for two selected models, applied to the testing cohort. Receiver operating characteristic curve.

Presentation transcript:

Associations of VO2peak to significant predictors. Associations of VO2peak to significant predictors. Influence of age (A), body mass index (BMI) (B), systolic blood pressure (SBP) (C), resting heart rate (RHR) (D), physical activity index (E) and patient global assessment (PGA) (F) on VO2peak, based on the multivariable model including age, gender, BMI, RHR, smoking, SBP, physical activity index and PGA. Circles: women; diamonds: men; grey areas: 95% CIs. Marthe Halsan Liff et al. RMD Open 2019;5:e000912 Copyright © BMJ Publishing Group & EULAR. All rights reserved.